Copenhagen, Denmark (ots/PRNewswire) - - Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Combination With CHOP as Front Line Treatment of Follicular NHL. Genmab A/S (CSE: GEN) announced today it has initiated a Phase II study of ofatumumab (HuMax-CD20(R)) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with previously untreated follicular ...
Copenhagen, Denmark (ots/PRNewswire) - Genmab A/S (CSE: GEN) announced today that cutaneous T-cell lymphoma (CTCL) patients in the HuMax-CD4 Phase II studies achieved long lasting responses, with an average response duration of more than 6.6 months. This duration of response data is based on an analysis of responding mycosis fungoides (MF) patients at all dose ...
McLean, Virginia (ots-PRNewswire) - Genmab A/S (CSE: GEN and Neuer Markt: GE9D), Medarex (Nasdaq: MEDX), and Glaucus Proteomics B.V., a privately held company incorporated in The Netherlands, announced today that they have entered into a collaboration to develop new antibody therapeutic products to novel disease ...